Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $160.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective hoisted by HC Wainwright from $150.00 to $160.00 in a research note released on Thursday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on NBIX. Mizuho raised their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a neutral rating in a report on Thursday, February 8th. JPMorgan Chase & Co. raised their target price on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an overweight rating in a report on Wednesday, March 20th. Citigroup cut their price objective on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a neutral rating for the company in a report on Thursday, February 8th. Barclays lifted their price objective on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an overweight rating in a report on Tuesday, January 23rd. Finally, Wells Fargo & Company raised shares of Neurocrine Biosciences from an equal weight rating to an overweight rating and lifted their price objective for the company from $140.00 to $170.00 in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and a consensus target price of $147.88.

Neurocrine Biosciences Trading Up 0.6 %

NASDAQ NBIX opened at $140.71 on Thursday. The company has a fifty day simple moving average of $137.37 and a two-hundred day simple moving average of $129.00. The stock has a market cap of $14.16 billion, a P/E ratio of 38.76 and a beta of 0.28. Neurocrine Biosciences has a 12-month low of $89.04 and a 12-month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The business had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. During the same quarter last year, the company posted $0.88 earnings per share. The business’s quarterly revenue was up 25.0% on a year-over-year basis. As a group, sell-side analysts forecast that Neurocrine Biosciences will post 4.78 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the transaction, the insider now directly owns 40,778 shares in the company, valued at $5,438,154.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the transaction, the insider now directly owns 40,778 shares in the company, valued at $5,438,154.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David W. Boyer sold 1,328 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $135.41, for a total transaction of $179,824.48. Following the transaction, the insider now owns 4,895 shares in the company, valued at $662,831.95. The disclosure for this sale can be found here. Over the last three months, insiders have sold 181,547 shares of company stock worth $25,039,887. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. FCF Advisors LLC acquired a new position in Neurocrine Biosciences in the 4th quarter valued at about $1,157,000. abrdn plc boosted its holdings in Neurocrine Biosciences by 2,503.0% in the 4th quarter. abrdn plc now owns 83,633 shares of the company’s stock valued at $11,019,000 after purchasing an additional 80,420 shares during the last quarter. Redhawk Wealth Advisors Inc. acquired a new position in Neurocrine Biosciences in the 4th quarter valued at about $1,245,000. HealthInvest Partners AB acquired a new position in Neurocrine Biosciences in the 4th quarter valued at about $1,662,000. Finally, Roman Butler Fullerton & Co. acquired a new position in Neurocrine Biosciences in the 4th quarter valued at about $1,256,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.